Meeting
2021 ASCO Annual Meeting
Olanzapine or dexamethasone, with 5-HT3 receptor antagonist and NK-1 receptor antagonist, to prevent nausea and vomiting induced by cisplatin-based doublet chemotherapy: A non-inferiority, prospective, multi-centered, randomized, controlled, phase III clinical trial.
Authors
Zhigang Liu
The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China
Zhigang Liu , Yuling Zhou , Shuang Yang , Wei-neng Feng , Ming-Yuan Chen , Xiong Zou , Guang Han , Jie Tang , Guorong Zou , Yu-Xiang He , Lemeng Zhang , Lei Cui , Hualin Chen , Guo Li , Shan Jiang , Jin Gao , Lin Xiao , Qun Zhang , Wei Yi , Chenghui Huang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT04437017
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS12133)
DOI
10.1200/JCO.2021.39.15_suppl.TPS12133
Abstract #
TPS12133
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).
First Author: Rudolph M. Navari
Poster
2015 Breast Cancer Symposium
Phase III study of APF530 versus ondansetron with a neurokinin 1 antagonist + corticosteroid in preventing highly emetogenic chemotherapy-induced nausea and vomiting: MAGIC trial.
First Author: Ian D. Schnadig
Poster
2023 ASCO Annual Meeting
A phase III, double-blind, non-inferiority, randomized controlled trial of antiemetic prophylaxis for highly emetogenic chemotherapy without dexamethasone: CINV POD study.
First Author: Venkatraman Radhakrishnan
Poster
2017 ASCO Annual Meeting
Phase III study of NEPA, a fixed combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV).
First Author: Li Zhang